Last reviewed · How we verify
Dual Integrin Antagonist
Dual Integrin Antagonist is a Integrin antagonist Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 2 development.
Blocks multiple integrin receptors to inhibit cell adhesion and signaling pathways involved in disease processes.
A Dual Integrin Antagonist was studied in a clinical trial for the treatment of asthma. The trial, which was completed in 2007, evaluated the efficacy of the Dual Integrin Antagonist in patients with asthma not treated with inhaled corticosteroids.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Hoffmann-La Roche is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dual Integrin Antagonist |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Integrin antagonist |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Integrins are transmembrane receptors that facilitate cellular adhesion and signal transduction. By antagonizing multiple integrin subtypes simultaneously, this dual-targeting approach may provide broader therapeutic effects in conditions where integrin-mediated pathways contribute to disease pathology.
Approved indications
Common side effects
Key clinical trials
- Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma (PHASE2)
- Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dual Integrin Antagonist CI brief — competitive landscape report
- Dual Integrin Antagonist updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Dual Integrin Antagonist
What is Dual Integrin Antagonist?
How does Dual Integrin Antagonist work?
Who makes Dual Integrin Antagonist?
What drug class is Dual Integrin Antagonist in?
What development phase is Dual Integrin Antagonist in?
Related
- Drug class: All Integrin antagonist drugs
- Manufacturer: Hoffmann-La Roche — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing